{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:15Z","timestamp":1792804155245,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.arcmed.2024.103058","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T10:27:46Z","timestamp":1722508066000},"page":"103058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Activity Prediction Modeling Based on a Combination of Growth Differentiation Factor 15 and Serum Biomarker Levels in Dermatomyositis and Polymyositis"],"prefix":"10.1016","volume":"55","author":[{"given":"Qiong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-4557","authenticated-orcid":false,"given":"Siyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2024.103058_bib0001","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00019052-199606000-00015","article-title":"The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis","volume":"9","author":"Dalakas","year":"1996","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0002","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.bbadis.2014.05.034","article-title":"Dermatomyositis, polymyositis and immune-mediated necrotising myopathies","volume":"1852","author":"Luo","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.arcmed.2024.103058_bib0003","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/imj.15358","article-title":"Idiopathic inflammatory myopathies: a review","volume":"51","author":"Ashton","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.arcmed.2024.103058_bib0004","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.autrev.2017.07.021","article-title":"Using multi-omics methods to understand dermatomyositis\/polymyositis","volume":"16","author":"Gao","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.arcmed.2024.103058_bib0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/00002281-199611000-00002","article-title":"Assessment of disease activity and its sequelae in children and adults with myositis","volume":"8","author":"Rider","year":"1996","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0006","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874312901206010054","article-title":"Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups","volume":"6","author":"Volochayev","year":"2012","journal-title":"Open Rheumatol J"},{"key":"10.1016\/j.arcmed.2024.103058_bib0007","doi-asserted-by":"crossref","unstructured":"Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S118\u2013S157.","DOI":"10.1002\/acr.20532"},{"key":"10.1016\/j.arcmed.2024.103058_bib0008","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.40064","volume":"69","author":"Aggarwal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0009","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/BOR.0b013e3283317b31","article-title":"Role of cytokines and chemokines in idiopathic inflammatory myopathies","volume":"21","author":"De Paepe","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0010","first-page":"222","article-title":"Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients","volume":"34","author":"Hulejova","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0011","doi-asserted-by":"crossref","first-page":"e12849","DOI":"10.1111\/nan.12849","article-title":"Myostatin in idiopathic inflammatory myopathies: Serum assessment and disease activity","volume":"49","author":"Mahoudeau","year":"2023","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0012","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/rheumatology\/keaa305","article-title":"Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity","volume":"60","author":"Watanabe","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arcmed.2024.103058_bib0013","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12967-019-02176-z","article-title":"Correlation of PMN elastase and PMN elastase-to-neutrophil ratio with disease activity in patients with myositis","volume":"17","author":"Wu","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.arcmed.2024.103058_bib0014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cyto.2018.12.023","article-title":"Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis","volume":"116","author":"Andres Cerezo","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.arcmed.2024.103058_bib0015","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s10067-018-04418-9","article-title":"Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients","volume":"38","author":"Zhou","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0016","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/0004563218786979","article-title":"Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis","volume":"56","author":"Gao","year":"2019","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.arcmed.2024.103058_bib0017","article-title":"Clinical Features and Cytokine Profile in Myositis Patients with Anti-EJ Autoantibodies Detected by a Novel Immunoprecipitation Assay","volume":"2019","author":"Yang","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.arcmed.2024.103058_bib0018","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.38676","article-title":"Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis","volume":"66","author":"Bellutti Enders","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0019","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kead654","article-title":"The emerging role of Growth Differentiation Factor 15 as a potential disease biomarker in juvenile dermatomyositis","author":"Duvvuri","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arcmed.2024.103058_bib0021","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.3390\/cells10112990","article-title":"The Role of GDF15 as a Myomitokine","volume":"10","author":"Johann","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.arcmed.2024.103058_bib0022","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/10408363.2019.1615034","article-title":"Growth differentiation factor 15: A novel biomarker with high clinical potential","volume":"56","author":"Desmedt","year":"2019","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.arcmed.2024.103058_bib0023","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","article-title":"Growth\/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint","volume":"11","author":"Wischhusen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0024","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/rheumatology\/keaa721","article-title":"The diagnostic value of GDF-15 for myocardial involvement in idiopathic inflammatory myopathy","volume":"60","author":"Qiu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.arcmed.2024.103058_bib0025","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000675","article-title":"Growth differentiation factor 15 is increased in stable MS","volume":"7","author":"Amstad","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.arcmed.2024.103058_bib0026","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/1744666X.2022.2021879","article-title":"Growth differentiation factor-15 as an emerging biomarker for identifying myositis","volume":"18","author":"De Paepe","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2164-15-91","article-title":"Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies","volume":"15","author":"Kalko","year":"2014","journal-title":"BMC Genomics"},{"key":"10.1016\/j.arcmed.2024.103058_bib0028","doi-asserted-by":"crossref","first-page":"e48804","DOI":"10.15252\/embr.201948804","article-title":"Muscle-derived GDF15 drives diurnal anorexia and systemic metabolic remodeling during mitochondrial stress","volume":"21","author":"Ost","year":"2020","journal-title":"EMBO Rep"},{"key":"10.1016\/j.arcmed.2024.103058_bib0029","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mito.2019.10.005","article-title":"Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy","volume":"50","author":"Poulsen","year":"2020","journal-title":"Mitochondrion"},{"key":"10.1016\/j.arcmed.2024.103058_bib0030","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1212\/WNL.0000000000003374","article-title":"FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders","volume":"87","author":"Lehtonen","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.arcmed.2024.103058_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154966","article-title":"The myokine GDF-15 is a potential biomarker for myositis and associates with the protein aggregates of sporadic inclusion body myositis","volume":"127","author":"De Paepe","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.arcmed.2024.103058_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231064","article-title":"Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5","volume":"15","author":"Oikawa","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.arcmed.2024.103058_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13101369","article-title":"Retrospective Study Shows That Serum Levels of Chemokine CXCL10 and Cytokine GDF15 Support a Diagnosis of Sporadic Inclusion Body Myositis and Immune-Mediated Necrotizing Myopathy","volume":"13","author":"De Paepe","year":"2023","journal-title":"Brain Sci"},{"key":"10.1016\/j.arcmed.2024.103058_bib0034","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2024.103058_bib0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2024.103058_bib0036","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arcmed.2024.103058_bib0037","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-2377-11-143","article-title":"Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China","volume":"11","author":"Shu","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0038","doi-asserted-by":"crossref","first-page":"e24876","DOI":"10.1002\/jcla.24876","article-title":"Low serum level of citrullinated histone H3 in patients with dermatomyositis","volume":"37","author":"Wang","year":"2023","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.arcmed.2024.103058_bib0039","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.arcmed.2024.103058_bib0040","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/jamaneurol.2014.4740","article-title":"The Future of Research in Myasthenia","volume":"72","author":"Richman","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0041","doi-asserted-by":"crossref","first-page":"e12799","DOI":"10.1111\/acel.12799","article-title":"Plasma proteomic signature of age in healthy humans","volume":"17","author":"Tanaka","year":"2018","journal-title":"Aging Cell"},{"key":"10.1016\/j.arcmed.2024.103058_bib0042","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/gerona\/gly153","article-title":"Human Aging and Longevity Are Characterized by High Levels of Mitokines","volume":"74","author":"Conte","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"10.1016\/j.arcmed.2024.103058_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22209","article-title":"Red blood cell distribution width and neutrophil to lymphocyte ratio are correlated with disease activity of dermatomyositis and polymyositis","volume":"32","author":"Gao","year":"2018","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.arcmed.2024.103058_bib0044","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arcmed.2024.103058_bib0045","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arcmed.2024.103058_bib0046","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.39200","article-title":"Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated","volume":"67","author":"Almeida","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arcmed.2024.103058_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1404047","article-title":"Different roles of circulating and intramuscular GDF15 as markers of skeletal muscle health","volume":"15","author":"Chiariello","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.arcmed.2024.103058_bib0048","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s13311-015-0394-2","article-title":"Immunotherapies for Immune-Mediated Myopathies: A Current Perspective","volume":"13","author":"Needham","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arcmed.2024.103058_bib0049","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440924001103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440924001103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T23:26:03Z","timestamp":1731972363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440924001103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0188440924001103"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2024.103058","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity Prediction Modeling Based on a Combination of Growth Differentiation Factor 15 and Serum Biomarker Levels in Dermatomyositis and Polymyositis","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2024.103058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103058"}}